iBio Inc. (IBIO) reported QQ3 2024 results with no revenue recognized for the quarter, a substantive net loss, and a cash burn that was largely offset by financing activity. The quarter’s metric highlights include a gross loss of $0.332 million on $0 revenue, operating loss of $3.626 million, and a net loss of $3.172 million, or $0.85 per share, on weighted average shares of 3.713 million. EBITDA declined to a negative $2.251 million as the company continued to fund R&D and G&A expenses while pursuing contract development and manufacturing opportunities in Bioprocessing and Biopharmaceuticals segments.
Cash flow remained negative from operations at $3.654 million, but iBio generated net cash inflows of $5.025 million from financing activities, primarily through common stock issuance, supporting a year-to-date cash balance ending at $6.216 million. The balance sheet shows total assets of $50.154 million and total liabilities of $25.291 million, leaving total stockholders’ equity of $24.863 million. Cumulatively, retained earnings sit at a sizeable deficit of $306.069 million, underscoring the ongoing dependence on external funding and the importance of near-term liquidity management and potential contract milestones or partnerships.
From a competitive and market perspective, iBio operates in a high-visibility, R&D-intensive segment with limited near-term revenue generation. The QQ3 results suggest execution focus remains on advancing the two Segments (Biopharmaceuticals and Bioprocessing) and exploring collaborations or license arrangements that could unlock revenue. The company’s immediate outlook depends on securing commercial or milestone-based contracts, additional financing, and cost-control measures to extend the liquidity runway as it scales its CDMO capabilities.